

For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

**UNITED THERAPEUTICS TO HOLD OVARIAN CANCER INVESTOR AND
ANALYST DAY ON JUNE 22, 2006 IN SILVER SPRING, MARYLAND**

Silver Spring, MD, May 25, 2006: United Therapeutics Corporation (NASDAQ: UTHR) and its wholly-owned subsidiary Unither Pharmaceuticals, Inc. today announced that they will host an Investor and Analyst Day on Thursday, June 22, 2006 at their new laboratory located at 1040 Spring Street, Silver Spring, Maryland 20910 from 10:00 a.m. to 1:00 p.m. Eastern time. The event will focus on United Therapeutics' monoclonal antibody OvaRex® which is currently being studied in Phase III clinical trials for ovarian cancer. The event will include presentations from management focused on OvaRex and United Therapeutics' monoclonal antibody platform in general. The event will also include a tour of the new laboratory.

Those interested in attending this event are asked to submit a reservation stating their name and affiliation by email to OVAREXRSVP@unither.com.

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.
